LifeMine Therapeutics

LifeMine Therapeutics is a clinical-stage biopharmaceutical company that applies what it calls Top-Down Drug Discovery, using digital genomic search across fungal genomes to identify genetically encoded small molecules (GEMs) with novel structures and mechanisms. The company's platform combines human genetics and genomics, bioinformatics, machine learning, and synthetic biology, including genome mining and recombinant overexpression, to convert evolutionary insights from fungi into drug candidates. Historically the platform was described as producing candidates across major disease areas with an initial emphasis on oncology and immune modulation; current disclosed focus is transplantation and immunology.

The lead program, LIFE-001, is a structurally and mechanistically novel calcineurin activation inhibitor (CNai) developed for prevention of organ transplant rejection. Unlike tacrolimus and cyclosporine, which act indirectly through a molecular-glue mechanism, LIFE-001 is described as binding directly to a previously unseen site on calcineurin, and is formulated as a long-acting injectable intended to smooth pharmacokinetics and limit exposure in the brain and peripheral tissues. The first participant was dosed in a first-in-human Phase 1 trial in April 2025; the company plans a Phase 2 kidney transplant study and a Phase 1b islet cell transplant study in early 2027, with islet data possible by end-2027 and kidney transplant results expected in 2028. A second program targeting autoimmune disorders follows LIFE-001; management said it declined to pursue Crohn's disease and lupus nephritis with the lead asset because of the competitive landscape.

Founding story

Sources give differing founding dates: one aggregator lists 2016 while BioPharma Dive and another profile state the company was formed in 2017. It was co-founded by Gregory Verdine, Ph.D., a former Harvard University chemical biologist and serial biotech entrepreneur who serves as President and CEO, together with company-builder WeiQing Zhou (Chief Operating Officer) and, per one profile, Richard Klausner, M.D. The founding premise was that fungi have evolved optimized, drug-like natural products that conventional discovery approaches had largely overlooked, and that these could be accessed systematically through genome mining.

Business model

LifeMine is a venture-funded, privately held drug developer that discovers and develops proprietary small-molecule therapeutics on its own platform, funding operations through equity financing rounds and at least one pharma research collaboration (GSK, 2023). Management has said it is considering commercializing LIFE-001 itself and has not ruled out an eventual IPO after data from its first two human studies.

No product revenue is disclosed; the company is pre-commercial and funded by venture capital, with a research collaboration with GSK reported in 2023.

Traction

LIFE-001 is in an ongoing Phase 1 trial, with early data reported in 120 adults showing an improved profile relative to legacy anti-transplant medicines and no clinically meaningful renal, metabolic or cardiovascular safety signals observed to date, per the company. Cumulative private financing is reported at $558M (FinSMEs) to roughly $580M (BioPharma Dive). Investors include Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus, ARCH Venture Partners, Fidelity, Foresite Capital, F-Prime Capital, Mubadala, Blue Pool Capital, MRL Ventures Fund and others.

Latest developments

On August 6, 2026 LifeMine announced a $263M combined financing to accelerate clinical development of LIFE-001. Reporting on the composition differs: BioPharma Dive and FinSMEs describe a $75M Series D (raised in Q4 2025) plus a $188M Series E led by Milky Way Investments, while BioSpace describes the $188M tranche as an oversubscribed Series F. Participants named include Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus and ARCH Venture Partners. Proceeds are earmarked for a Phase 2 kidney transplant study, a Phase 1b islet cell transplant study, and pipeline expansion in transplantation and immunology. The company also appointed Yves Zinggeler as chief commercial officer. Management said it opted for late-stage venture rounds instead of an IPO for now.